Citation tools

Hofman, Michael et al "High activity, pain reduction and low toxicity with Lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): results of a phase II prospective trial." Journal of Nuclear Medicine 59.supplement 1 (2018): 531. Web. 26 April. 2025.

Citation Manager Formats